GoodRx Holdings (GDRX) Amortization of Deferred Charges (2019 - 2026)

GoodRx Holdings has reported Amortization of Deferred Charges for 8 years, with the latest figure at $925000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges fell 14.83% year-over-year to $925000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 40.06% YoY) and the FY2025 annual result came in at $4.0 million, up 60.47% from the prior year.
• Amortization of Deferred Charges retreated to $925000.0 in Q1 2026 per GDRX's latest filing, from $944000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.2 million in Q3 2025 and troughed at -$484000.0 in Q4 2024.
• A 5-year average of $836705.9 and a median of $852000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges tumbled 157.41% in 2024, then surged 295.04% in 2025.
• Over 5 years, Amortization of Deferred Charges stood at $851000.0 in 2022, then retreated by 0.94% to $843000.0 in 2023, then sank by 157.41% to -$484000.0 in 2024, then soared by 295.04% to $944000.0 in 2025, then slipped by 2.01% to $925000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $925000.0, $944000.0, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.